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Introduction
Peripheral T cell lymphomas (PTCLs) are highly heterogenous, 
comprising at least 30 post-thymic (i.e., mature) T or NK cell–
derived entities according to the current 2016 WHO classification 
(1). PTCLs represent approximately 5%–10% of all non-Hodgkin 
lymphomas (NHLs) in Western countries, and the incidence is even 
higher in Asia and Central and South America (2). Aside from cuta-
neous mycosis fungoides (MF) and Sézary syndrome (SS), angio-
immunoblastic T cell lymphoma (AITL) and PTCL–not otherwise 
specified (PTCL-NOS) are the most prevalent diseases. Compared 
with their B cell counterpart, most PTCLs have a poor prognosis, 
with a 5-year overall survival rate barely exceeding 30%, and che-
motherapy regimens that cure many patients with B cell NHL have 
thus far been relatively ineffective against PTCLs, emphasizing the 
need for innovative approaches (2).
T cell receptor (TCR) signaling is the major growth-reg-
ulatory machinery of normal T cells. Evidence supporting its 
important role in the biology of various PTCL entities has recent-
ly been published. A specific translocation (t[5;9] [q33;q22]) in 
some PTCLs that leads to the generation of an abnormal ITK-
SYK fusion protein, constitutive tyrosine kinase activity, and 
the development of PTCLs been reported in a mouse model (3). 
Recurrent activating mutations in TCR and costimulatory recep-
tor pathway genes such as RHOA, FYN, LCK, PRKCQ, PLCG1, 
VAV1, CD28, and CARD11 have been described in several PTCL 
entities such as cutaneous T cell lymphomas (CTCLs) (4–6), adult 
T cell leukemia/lymphoma (ATLL) (7), AITL, and PTCL-NOS 
(8–12). Aside from the ITK/SYK translocation and the RHOA 
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expansion of large T lymphocytes (CD3+Thy1+CD19–) (Supple-
mental Table 1 and Supplemental Figure 2B). High-throughput 
sequencing of the TCR repertoire showed monoclonal expan-
sion of T lymphocytes in all lymphoproliferations tested (Figure 
1D and Supplemental Table 2). Altogether, the results obtained 
in the p53KO>CD3εKO mice defined these monoclonal T lym-
phocyte expansions as PTCLs, in contrast to the WT>CD3εKO 
mice that did not develop PTCL (Figure 1B). To confirm the neo-
plastic nature of these proliferations, we transferred total cells 
from enlarged spleens or livers into WT C57BL/6 recipient mice. 
These recipient mice developed all the characteristics of the 
donor mice, with rapid enlargement of LNs, splenomegaly, and 
hepatomegaly requiring euthanasia (Supplemental Figure 2C).
Murine PTCLs (mPTCLs) downregulated T cell markers 
such as TCRβ and CD5, did not express TCRγδ, were not CD1d 
restricted, and were mostly CD8+ (Supplemental Figure 2, D and 
E). They were also CD62LloCD44+CD122+CD25–CD127–, defin-
ing an effector memory phenotype (Figure 1E and Supplemental 
Figure 2E). Activation markers such as CD54 and B220 were sig-
nificantly upregulated in all mPTCLs compared with expression 
in normal T cells (Figure 1E), whereas PD1 and LAG3 were only 
expressed in 40% of mPTCL cells (Supplemental Figure 2E). 
Finally, the death receptor Fas/CD95, which is highly expressed 
in activated T cells, was strongly downregulated in mPTCL cells 
(Supplemental Figure 2F).
TCR and IL-15 are not required for mPTCL survival. To confirm 
the involvement of chronic TCR stimulation in mPTCL devel-
opment, we studied the gene expression profile (GEP) of these 
mPTCLs in comparison with normal resting and activated T 
cells. Previous reports established that gene expression of CD247 
(CD3ζ), LCK, and LAT was downregulated upon repeated stimu-
lation arising in the context of chronic infection or autoimmunity 
(29). We thus focused on the TCR signaling pathway using gene 
set enrichment analysis (GSEA), as previously described in NKT 
lymphomas (23). The expression of genes involved in the TCR sig-
naling pathway, in particular CD247 (CD3ζ), LCK, and LAT, was 
markedly downregulated compared with expression in normal T 
cells (P = 0.007) (Figure 2, A and B), supporting the role of chronic 
TCR stimulation in this model of lymphomagenesis.
To further investigate the role of TCR signaling in these mPT-
CLs and, more specifically, to ascertain whether constitutive TCR 
signaling is required for mPTCL survival, we used cyclosporine 
A (CsA), a calcineurin inhibitor known to strongly suppress TCR 
signaling. Although in vivo administration of CsA has already 
been shown to inhibit PTCL survival in a TCR signaling–depen-
dent manner (22, 23), it did not prolong the survival of C57BL/6 
mice transferred with PTCL cells from our model, suggesting that 
mPTCL survival did not rely on constitutive TCR activation (Fig-
ure 2C). To further test this point, mPTCL cells were genetically 
invalidated for the TCR/CD3 signaling complex using sgRNA/
Cas9 ribonucleoprotein (RNP) targeting the Cd3e gene to achieve 
a protein knockdown of CD3ε at rates of more than 85% (Supple-
mental Figure 3A). Mice transferred with Cd3ε-invalidated mPT-
CL cells did not survive longer than those transferred with mPT-
CL cells transfected with control sgRNA/Cas9 RNP (Figure 2D), 
confirming that constitutive TCR signaling was not required for 
mPTCL survival.
G17V mutation (13, 14), the role of these genomic alterations in 
PTCL biology remains elusive, as they may constitute acquired 
secondary events. In the past years, chronic TCR stimulation has 
been suspected in the lymphomagenesis of some PTCLs (15). For 
instance, enteropathy-associated T cell lymphoma (EATL) is a 
well-recognized complication of celiac disease that is thought to 
be linked to chronic antigenic stimulation (16). However, recent 
work highlighted the finding that neoplastic cells are not specif-
ic to gliadin, the main antigen responsible for celiac disease, and 
may be transformed through chronic bystander activation (17). 
T cell large granular lymphocytic leukemia (T-LGL), SS, hepato-
splenic T cell lymphoma (HSTL), and breast implant–associated 
anaplastic large cell lymphoma (ALCL) also seem to occur in a 
setting of sustained immune stimulation (18–21), although direct 
evidence of a driving role of chronic TCR stimulation is lacking. 
Finally, conventional T cell lymphomagenesis has been demon-
strated to be dependent on TCR signaling in murine models, such 
as in Snf5 conditionally inactivated T cells (22), while exposure to 
chronic bacterial antigens drives lymphomagenesis of unconven-
tional NKT cells in p53–/– mice (23, 24).
Collectively, these clinical and experimental data point 
toward a central role for TCR signaling in PTCL, although a 
direct link between chronic TCR stimulation and conventional T 
cell lymphomagenesis has not been formally established. In this 
study, we attempted to unravel the mechanisms of T cell lympho-
ma development in the context of chronic TCR stimulation using 
conventional p53–/– T cells, since TP53 mutations or copy number 
alterations have been recurrently described in several PTCL enti-
ties (4, 6, 25–27).
Results
Chronic TCR stimulation drives p53–/– T cell lymphomagenesis. To 
mimic chronic TCR stimulation, we took advantage of T cell 
homeostatic proliferation or lymphopenia-induced prolifera-
tion (LIP) (28), which is driven by cytokines and chronic TCR 
signaling generated by self–MHC-TCR interactions. To this end, 
purified mature T cells from WT or p53–/– mice were transferred 
into CD3ε–/– recipient mice (which lack mature T cells). In this 
condition, transferred WT or p53–/– T lymphocytes rapidly prolif-
erated in the spleen and lymph nodes (LNs) (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/JCI139675DS1), acquired activated and 
memory phenotypes (Supplemental Figure 1B), and expanded in 
CD3ε–/– recipient mice (Supplemental Figure 1C). Whereas 75% 
of CD3ε–/– recipient mice receiving WT T lymphocytes (hereaf-
ter referred to as WT>CD3εKO mice) were still alive 450 days 
after transfer, all mice transferred with p53–/– T lymphocytes 
(hereafter referred to as p53KO>CD3εKO mice) had died with-
in 343 days (median survival = 224 days; Figure 1A). As a con-
trol, we also transferred p53–/– T lymphocytes into WT recipient 
mice (hereafter referred to as p53KO>WT mice), which triggered 
neither homeostatic proliferation (Supplemental Figure 1D) nor 
death even 450 days after transfer (Figure 1A). Sixty percent of 
the p53KO>CD3εKO mice exhibited adenomegalies, spleno-
megaly, and hepatomegaly (Figure 1B and Supplemental Figure 
2A) associated with a complete effacement of the normal LN, 
spleen, and liver architecture (Figure 1C), as well as massive 
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Figure 1. Chronic TCR stimula-
tion promotes T cell lymphom-
agenesis. (A) Kaplan-Meier 
survival curves for CD3ε–/– mice 
receiving WT cells (WT>CD3εKO, 
squares, n = 20) or p53–/– T cells 
(p53KO>CD3εKO, circles, n = 80) 
and for WT (C57BL6 CD451.1) 
mice receiving p53–/– T cells 
(CD451.2) (p53KO>WT, triangle, n 
= 11). In the WT>CD3εKO group, 
recipient mice alive on day 450 
were sacrificed and evaluated. 
For the p53KO>WT group, all 
mice were still alive 450 days 
after transfer. ****P < 0.0001, 
by log-rank test and Holm’s post 
hoc correction. For the p53KO>C-
D3εKO group, the circles are 
colored according to the mouse’s 
cause of death: data points for 
mice that died of PTCL are shown 
in red, thymic lymphomas (TL) in 
black, and others (no lymphoma) 
in white. (B) Spectrum of causes 
of death for p53KO>CD3εKO or 
WT>CD3εKO mice. Mice alive 
on day 450 were categorized as 
“alive” and were then sacrificed. 
(C) Representative histological 
micrographs of formalin-fixed, 
H&E- or anti-CD3–stained liver, 
spleen, and LNs obtained from a 
mPTCL. Scale bars: 100 μm; 400 
μm. (D) Pie chart representation 
of TCRVβ clonality in 3 represen-
tative mPTCL samples among 16 
tested. (E) Surface expression of 
CD62L, CD44, CD122, CD54, and 
B220 measured by flow cytome-
try (ΔMFI) in mPTCL cells (n = 26) 
compared with normal T cells (n 
= 3). P values were determined by 
Mann-Whitney U test comparing 
mPTCL cells with control T cells.
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opment (30, 32), we also tested the effect of genetic invalidation of 
CD122 or an anti-CD122–blocking antibody on mPTCL survival. 
Transfer of mPTCL with pharmacological or genetic invalidation 
of CD122 did not increase the survival of C57BL/6 recipient mice 
(Figure 2D and Supplemental Figure 3, A and D), demonstrating 
that IL-15 was not required for mPTCL survival in vivo. To rule out 
other cytokines involved in T cell survival, we treated WT synge-
neic recipient mice transferred with mPTCLs with inhibitors of 
JAK1/2 (ruxolitinib) or JAK1/3 (tofacitinib), which participate in 
IL-2R, IL-4R, IL-7R, and IL-15R signaling. Neither inhibitor had 
an effect on mPTCL survival (Supplemental Figure 3E).
Ectopic expression and activation of SYK in murine and human 
PTCLs. To identify molecular mechanisms involved in mPTCL 
survival, we first used a kinase array assay to evaluate the con-
stitutively activated tyrosine kinases in mPTCLs compared with 
normal T cells. Among the 144 peptides present on the array, 43 
and 37 peptides associated with SYK and Zap70 activity, respec-
tively, were phosphorylated in the mPTCL lysates (Figure 3A). 
Kinases upstream of SYK or ZAP70, such as BLK, LCK, and FYN, 
were also constitutively activated in mPTCLs (Figure 3A). Since 
We next analyzed whether deliberate TCR activation of 
mPTCL cells may affect survival of these mice in vivo. Injec-
tion of an agonist anti-CD3 mAb did not modify the survival of 
most CD3ε–/– recipient mice transferred with PTCL cells (Sup-
plemental Figure 3B), suggesting that the TCR was not involved 
in mPTCL survival in vivo.
Having excluded TCR signaling as the major prosurvival path-
way in mPTCLs, we then speculated that cytokines known to be 
crucial for T cell proliferation and/or survival may be implicated. 
Among the cytokines involved in T cell homeostatic proliferation, 
IL-15 plays a central role. Since the IL-15Rβ chain CD122 was high-
ly upregulated in mPTCLs (Figure 1E) and IL-15 was described as a 
proinflammatory cytokine responsible for genomic instability and 
T cell lymphoma/leukemia development (30–32), we investigated 
whether IL-15 was involved in mPTCL survival in our model. As a 
first approach, we transferred mPTCL cells into WT or IL-15–/– syn-
geneic mice and observed no difference in mPTCL development, 
since both groups of mice had similar survival curves (Supple-
mental Figure 3C). Keeping in mind the possible autocrine IL-15/
IL-15R loop described in CD8+ T cell lymphoma/leukemia devel-
Figure 2. TCR stimulation is required for lymphomagenesis but dispensable for mPTCL survival. (A) Heatmap of all genes included in the GSEA for the 
TCR signaling pathway in mPTCL cells compared with normal resting and activated T cells. (B) GSEA of a set of genes from the TCR signaling pathway. 
The downward deflection indicates enrichment of the TCR signaling pathway signature in normal T cells (P = 0.007, nominal permutation P value based on 
1000 permutations). NES, normalized enrichment score. (C) Kaplan-Meier survival curves for WT mice receiving mPTCL cells and treated with CsA (20 mg/
kg; n = 5) or vehicle alone (Ctrl; n = 5). P value was determined by log-rank test. Shown are results from 1 representative experiment among 3 tested with 
different PTCLs. (D) Kaplan-Meier survival curves for WT mice (n = 5 for each group) transferred with mPTCL cells genetically invalidated for Cd3e or Ilr2b 
using Alt-R CRISPR/Cas9 sgRNA targeting either of these genes, or transfected with control sgRNA (sgCtrl). *P < 0.05, by log-rank test and Holm’s post 
hoc correction. Data are representative of 2 independent experiments using different mPTCL cells.
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SYK was not expressed in normal mature T cells (Figure 3B), we 
first examined the presence of SYK in enriched mPTCL cells 
(purity >96%) by Western blotting and IHC. SYK was expressed 
in 8 of 9 and 4 of 5 mPTCLs tested, respectively (Figure 3, B and 
E, and see complete unedited blots in the supplemental material). 
We also confirmed the constitutive activation of SYK in mPTCLs 
compared with normal activated B and T cells using phospho-
flow analyses (Figure 3C). We then studied the expression and 
constitutive activation of classical downstream effectors of the 
SYK signaling pathway, such as PLCγ1, PLCγ2, AKT, ERK, and S6 
kinase. Surprisingly, we found that PLCγ2, which is generally not 
expressed in normal T cells (Figure 3B), was also expressed and 
constitutively activated in almost all mPTCLs tested (Figure 3, B 
and E). In contrast, the expression of PLCγ1, the most common 
PLCγ isoform in normal T cells (Figure  3B), was decreased in 7 
of 9 mPTCLs tested and showed only minor activation. Down-
stream kinases such as AKT, ERK, and S6 were also constitutively 
activated in all mPTCLs tested (Figure 3, B and D). Next, we per-
formed immunohistochemical analyses to assess the expression 
of SYK and PLCγ2 in a cohort of 157 primary human PTCLs rep-
resenting 7 different entities (Supplemental Table 3). We found 
that SYK was expressed in 60% of monomorphic epitheliotropic 
intestinal T cell lymphoma (MEITL) cells and 44% of anaplastic 
lymphoma kinase–positive (ALK+) ALCL cells (Figure 3F), as well 
as approximately 30% of T follicular helper PTCL (TFH-PTCL) 
cells, 20% of ALK– ALCL and HSTL cells, and 10% of PTCL-NOS 
cells. PLCγ2 was mostly coexpressed with SYK, with the excep-
tion of some ALCL (41%), PTCL-NOS (25%), and EATL cells, 
which only expressed PLCγ2 (Figure 3G). Taken together, these 
results highlight the expression of SYK and its downstream effec-
tors in both mPTCLs and a subset of human PTCL.
mPTCLs have a NK-like GEP. To define potential receptors 
upstream of the SYK and PLCγ2 signaling pathway, we compared 
the GEP of 9 mPTCLs with normal resting and activated T cells. 
The top downregulated and upregulated genes (log2 fold change 
[FC] >1; adjusted P < 0.05) between mPTCLs and normal T cells 
are depicted in the heatmap and volcano plot (Supplemental Fig-
ure 4A and Figure 4A). We found that Syk and Plcg2 were among 
the upregulated genes, confirming our previous results from 
kinome and Western blot studies. Surprisingly, many genes asso-
ciated with T cell differentiation or T cell identity, such as Cd4, 
Cd8, Cd5, Cd28, Thy1, and Bcl11b, were downregulated in mPT-
CLs, whereas genes associated with cytotoxicity and the NK cell 
lineage, such as Tyrobp (DAP12), Fcer1g, Ncr1 (NKp46), Cd244 
(2B4), and Gzma, were upregulated in comparison with expres-
sion levels in normal T cells (Figure 4A). To further refine the 
similarities between mPTCL and a potential normal cell subtype 
counterpart, we also compared these GEPs with a wide array of 
immunological cell populations ranging from immature T cells to 
NK and NKT cell subsets from the Immunological Genome Proj-
ect (ImmGen) mouse gene atlas and from our own previous cohort 
(23). Interestingly, hierarchical clustering based on the 1% most 
variably expressed genes revealed that most mPTCLs (5 of 9) clus-
tered with NK cells, whereas the others clustered with immature 
T cell populations, mainly NKT and γδT cells (Figure 4B). Clus-
tering was driven by 3 gene sets. The first one was highly enriched 
in “cancer proliferation” genes mostly expressed in mPTCL, NK 
cells, as well as in immature T cell populations. The second gene 
set was highly expressed in most mPTCLs, NK cells, NKT cells, as 
well as in effector and memory CD8+ T cells and associated with 
“antigen response” and “NK cell” signatures. The third gene set 
was negative in mPTCLs and included several T cell genes (Fig-
ure 4C and Supplemental Table 4). When focusing on differential 
gene expression between NK cells versus T cells (y axis) and mPT-
CLs versus T cells (x axis), most genes were comparably regulat-
ed in NK cells and mPTCLs (as evidenced on the diagonal of the 
figure), confirming the similarity between NK cells and mPTCLs 
(Figure 4D). When we investigating the genes upregulated in NK 
cells and mPTCLs (top-right quadrant), we found that many genes 
were associated with cytotoxicity, the NK cell receptor (NKR), 
and signaling of NK cell–activating receptors (NKaRs), suggesting 
a reprogramming of chronically stimulated T lymphocytes into 
NK-like PTCLs expressing several features of NK cells. Deletion 
of Bcl11b in mature T cells is known to result in reprogramming of 
T cells toward NK-like cells (33), demonstrating that Bcl11b is not 
only necessary for T cell development but also required to restrict 
mature T cell access to NK cell programs. We confirmed at the 
protein level the profound downregulation of Bcl11b in mPTCLs 
compared with expression in normal T cells (Supplemental Figure 
4B), suggesting that this downregulation may be a driver of NK 
cell–like reprogramming of mPTCL cells.
Murine PTCLs exhibit an epigenetic NK cell–like reprogramming. 
We next addressed whether NK cell–like reprogramming of mPT-
CL could be the consequence of chromatin remodeling using an 
assay for transposase-accessible chromatin with high-through-
put sequencing (ATAC-Seq). Applying the same analytic strategy 
of comparing mPTCL with immature and mature T cell popula-
tions as well as mature NK cells (from ImmGen and from our own 
Figure 3. SYK and downstream signaling pathways are constitutively 
activated in mPTCLs. (A) Volcano plot representation of the PamGene 
GeneGO analysis of tyrosine kinase activation in mPTCL cells (n = 18) 
compared with normal T cells (n = 3). The peptide contribution to upstream 
kinases was determined. (B) Western blots show the expression of SYK 
and ZAP70, as well as the expression and activation of PLCγ1, PLCγ2, AKT, 
and ERK in mPTCL cells compared with purified and stimulated (stim) 
normal B and T cells from WT mice, used as positive control. GAPDH was 
used as a loading control. (C) Representative FACS analysis of SYK tyrosine 
phosphorylation (pY342-SYK ) in mPTCL cells (red) in the basal state (red 
solid line) and after SYK pharmacological inhibition with P505-15 (red 
dashed line), as well as in control B cells (blue) in the basal state (blue 
dashed line) and after B cell receptor (BCR) stimulation (blue solid line), as 
measured by flow cytometry. Associated scatter plot shows SYK tyrosine 
phosphorylation expressed as the ΔMFI between basal and P505-15–
treated mPTCL cells (n = 8) compared with the ΔMFI between basal and 
BCR-stimulated B cells (n = 3), or between basal and TCR-stimulated T 
cells (n = 3). (D) Representative FACS analysis of pS235–236-S6 in mPTCL cells 
(red) or control T cells (gray) in the basal state (solid lines), as well as after 
mTORC1 pharmacological inhibition with rapamycin (dash lines). Asso-
ciated scatter plot shows the ΔMFI between basal and rapamycin-treat-
ed conditions in mPTCL cells (n = 6) compared with T cells (n = 3). (E) 
Immunohistochemical staining for CD3, SYK, and PLCγ2 in representative 
mPTCL cells (liver). Scale bars: 100 μm. (F) Immunohistochemical staining 
for CD30, SYK, and PLCγ2 in representative human ALK+ ALCL. (G) SYK and 
PLCγ2 expression in lymphoma cells from 7 different entities of human 
PTCLs. The TFH-PTCLs include AITL and PTCL-NOS with TFH-like features 
according to the 2016 WHO classification.
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cohort) to analyze the chromatin landscape, we identified 98,375 
high-quality open chromatin regions (OCRs). Hierarchical cluster-
ing or PCA analyses on all these peaks revealed (a) the global epi-
genetic proximity between mPTCLs and NK cells and, to a lesser 
extent, mature NKT and effector/memory CD8+ T cells, and (b) the 
more distant relation between mPTCL and immature T cell subsets 
(Figure 5A and Supplemental Figure 4C). This reinforces previous 
transcriptional data and demonstrates that mPTCL cells under-
went an epigenetic reprogramming toward NK cells. Supervised 
analysis further supported this chromatin remodeling of mPTCL 
cells toward NK cells. Compared with T cells from our own cohort, 
mPTCL cells showed greater accessibility to 3025 OCRs (FDR 
< 0.01) mostly associated with NK signatures from the ImmGen 
mouse gene atlas (FDR < 10–45) and lower accessibility to 4526 
Figure 4. Murine PTCLs downregulate T cell genes and express a NK-like transcriptome. (A) Volcano plot of genes differentially expressed between 
mPTCL cells (n = 9) and normal T cells (n = 6). The vertical black lines delimit the 2-FC effects. Upregulated genes in mPTCL cells compared with normal T 
cells are located on the right and downregulated genes on the left. Informative upregulated genes have been color-coded in red and the downregulated in 
blue. (B) Unsupervised clustering (using the Euclidean distance, Ward agglomeration method) based on the 1% of genes most variably expressed between 
immature and mature T cell populations as well as mature NK cells (data are from ImmGen and our own cohort). This clustering analysis generated 3 gene 
clusters (1, 2, and 3), defined on the left of the panel. (C) Representation of the 5 most highly significant C2 (Molecular Signatures Database [MSigDB]) 
gene set names of the 3 different gene clusters defined in B. (D) Comparison of genes differentially expressed between normal NK and T cells (y axis) and 
mPTCLs and normal T cells (x axis). Yellow dots correspond to genes differentially expressed, at a multiple-testing, adjusted P value of 0.05, between NK 
and T cells; blue dots correspond to genes differentially expressed between mPTCLs and T cells; and green dots represent genes differentially expressed in 
both conditions. The names of some of the most informative genes are indicated in the upper-right and lower-left quadrants.
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To confirm these epigenetic changes, we also performed 
genome-wide DNA methylation analysis using reduced represen-
tation bisulfite sequencing (RRBS) on T cells, NK cells, and mPT-
CL cells. PCA revealed that mPTCL cells clustered between T cells 
and NK cells (Supplemental Figure 4D). To compare these results 
with ATAC-Seq, we calculated for each sample the average meth-
ylation across ATAC-Seq peaks with a positive FC (FDR < 0.01, 
logFC >0, n = 144) and those with a negative FC (FDR < 0.01, log-
OCRs (FDR < 0.01) mostly associated with ImmGen α β T cell sig-
natures (FDR < 10–68) (Figure 5B). Further analysis of OCRs in the 
promoter regions involved in these NK signatures unveiled several 
genes, such as Gas7, Klrc1, Gzmk, Gzmb, Tyrobp, and Ncr1 (Figure 
5C). For instance, Tyrobp and Ncr1, which are highly expressed in 
mPTCLs compared with expression levels in normal T cells and 
NKT cells, exhibited greater OCR heights in mPTCL and NK cell 
versus T cell and NKT cell promoter regions (Figure 5D).
Figure 5. Epigenetic reprogramming of mPTCLs into NK-like cells. (A) Unsupervised clustering (Euclidean distance, Ward agglomeration method) of 
mPTCL cells, immature and mature T cell populations, as well as mature NK cells from ImmGen and from our own cohort, based on the normalized acces-
sibility of all 98,375 OCRs identified in ATAC-Seq. (B) Each bar represents a gene expression–based signature of a specific mouse cell population in the 
ImmGen atlas, colored according to broader population classes. Bar lengths (x axis) indicate the statistical significance of the overlap between genes in the 
signature and genes with differential chromatin accessibility in ATAC-Seq between mPTCL cells and normal T cells (ToppFun coexpression test FDR < 0.01). 
Cell populations whose representative genes harbor OCRs more accessible in normal T cells and mPTCL cells are presented respectively in the left and right 
panels. (C) Heatmap of chromatin accessibility in the 51 OCRs located in the promoter regions of genes involved in NK signatures presented in Figure 4E. 
(D) ATAC-Seq tracks from normal T cells, NKT cells, and NK cells, as well as mPTCL cells around Tyrobp and Ncr1 (average TMM-normalized CPMs per group 
in 50 bp wide bins). OCRs surrounded in red are significantly different (FDR < 5%) between conditions (mPTCL ≠ T and NKT; NK ≠ T and NKT).
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Since we cannot rule out the possibility that some of these NK 
genes were expressed by the tumor microenvironment, we inves-
tigated the expression of 15 NKRs or coreceptors in 65 primary 
human PTCL samples representing 9 different entities using 
multiparametric flow cytometry, allowing gating of only lympho-
ma cells. The expression of NKRs and coreceptors was variable 
from one entity to another, with SS and T-LGL expressing most 
of these receptors, whereas HSTL highly expressed half of these 
receptors, and PTCL-NOS expressed only a few NKRs (Figure 6, 
B and C, and Supplemental Figure 5H). Since the anti-KIR3DL2 
humanized cytotoxic antibody (lacutamab/IPH4102) showed 
encouraging clinical activity in a phase I trial for the treatment 
of CTCL (38), we focused on the expression of this KIR. Using a 
specific anti-KIR3DL2 antibody, we found that 9 of 14 (64%) SSs, 
5 of 7 T-LGLs (71%), 5 of 19 TFH-PTCLs (26%), and 0 of 6 (0%) 
PTCLs-NOS were positive (Figure 6C), representing a total of 
31% of the total cohort expressing KIR3DL2 (Supplemental Fig-
ure 5I). Of the 65 primary human samples tested, at least 1 KIR 
was expressed in 71%, at least 1 NKG2 receptor in 69%, and at 
least 1 natural cytotoxicity receptor (NCR) in 22% of PTCLs (Sup-
plemental Figure 5I), demonstrating the high prevalence of NKR 
expression in the total human PTCL cohort.
NKaRs are functional in mPTCLs. To determine whether 
NKaRs expressed on mPTCLs are functional, we first confirmed 
the expression of FcεRIγ and DAP12 (encoded by Tyrobp) adaptor 
proteins in most mPTCLs and NK cells (Figure 7A). Stimulation 
of mPTCLs through NKaRs NK1.1, NKp46, and NKG2D induced 
significant IFN-γ expression and degranulation, as illustrated by 
CD107 surface expression (Figure 7B). Stimulation with plate-
bound anti-CD3 led to similar results, demonstrating the cyto-
toxic phenotype of most mPTCLs. Triggering NKG2D, NKp46, or 
NK1.1 alone induced a lower but marked increase in degranulation 
and IFN-γ expression (Figure 7C). We observed that the effector 
functions of these NKaRs, alone or in combination, were com-
pletely inhibited by pretreatment with the SYK inhibitor P505-15, 
whereas IFN-γ and degranulation triggered by anti-CD3 were only 
marginally impaired, demonstrating the specific requirement for 
SYK in NKaR signaling but not in the TCR signaling pathway (Fig-
ure 7C). In addition, most mPTCLs expressed granzyme B, fur-
ther suggesting their potential cytotoxic activity and confirming 
at the protein level the data from transcriptomic analyses (Figure 
7D). Although some of these mPTCLs did not show any degranu-
lation or IFN-γ expression after NKaR stimulation, these NKaRs 
were still functional, as evidenced by their activation of the down-
stream effector PLCγ2 (Figure 7E). The activation of this effector 
by NKaR crosslinking was also dependent on SYK, as demonstrat-
ed by the decrease in PLCγ2 phosphorylation in the presence of 
the SYK inhibitor (Figure 7E).
mPTCL survival is dependent on NKaR signaling. Given the high 
expression of NKaR and the constitutive activation of downstream 
signaling in PTCLs, we postulated that NKaR signaling could con-
tribute to lymphoma cell survival. To test this hypothesis, mPTCL 
cells expressing NKG2D and NKp46 were genetically invalidated 
for Klrk1 (NKG2D), Ncr1 (NKp46), or both, to achieve a protein 
knockdown of NKG2D and NKp46 at rates above 90% (Supple-
mental Figure 6A). After transfer of the cells into syngeneic mice, 
we observed that the growth of mPTCLs invalidated for these 
FC <0, n = 239). The box plots in Supplemental Figure 4E show 
that the methylation profile of mPTCL cells was closer to that of 
NK cells for both peak sets.
Mature NK cell development is driven by transcription factors 
such as T-bet and Eomes (34). We therefore studied the expression of 
these 2 transcription factors in mPTCL cells compared with normal T 
and NK cells. Whereas T-bet and Eomes were not upregulated at the 
mRNA level in mPTCL cells compared with normal T cells (Figure 
4A), they were both significantly overexpressed at the protein level 
in mPTCL cells (Supplemental Figure 4F). This suggests that post-
transcriptional regulation, in addition to epigenetic modifications, is 
coordinated to induce NK-like reprogramming of mPTCL cells.
Activating and inhibitory NKRs are expressed in murine and 
human PTCLs. To further study NK-like reprogramming of 
mPTCL cells during chronic TCR stimulation, we analyzed 
NKR expression on 23 mPTCL cells using multiparametric flow 
cytometry to evaluate the expression of 6 NKaRs and 6 NK cell 
inhibitory receptors (NKiRs). Our data showed the expression of 
at least 1 NKR on 96% (22 of 23) of mPTCL cells and at least 1 
NKaR or NKiR on 66% (15 of 23) and 70% (16 of 23) of mPTCL 
cells, respectively (Supplemental Figure 5A). Among the NKaRs, 
NK1.1, NKG2D, 2B4, and CD16-32 were significantly expressed 
in most mPTCL cells compared with normal T cells (Figure 6A 
and Supplemental Figure 5B), whereas DNAM1 was expressed in 
only 56% (13 of 23) of mPTCL cells. We detected lower expres-
sion of NKiRs, with only KLRG1, Ly49A, and Ly49G2 signifi-
cantly expressed on mPTCL cells compared with normal T cells, 
whereas Ly49C and NKG2A were only expressed in 39% of mPT-
CL cells (Figure 6A and Supplemental Figure 5A). The expression 
of NKRs such as NKG2D or KLRG1 was associated with CD28 
downregulation (Supplemental Figure 5C), confirming at the pro-
tein level that NK cell–like reprogramming of mPTCL cells was 
associated with the acquisition of the NKR and the loss of T cell–
specific costimulatory receptors, such as CD28.
To explore whether this NK cell–like reprogramming may 
also take place in human PTCLs, we analyzed the expression of 
a set of genes associated with NK cells (e.g., NKR, NKR signaling 
molecules, cytotoxic molecules, etc.) in more than 250 human 
PTCL samples from previously published data sets (35, 36). NK/T 
lymphomas and HSTL originating mostly from NK cells and γδ T 
cells, respectively, expressed most of these genes, as previously 
reported (Supplemental Figure 5D and refs. 35, 37). More surpris-
ingly, this NK gene signature was also highly expressed in PTCLs 
originating from different entities such as ALCL-ALK+ and 
approximately half of the PTCL-NOSs analyzed. In particular, 
signaling molecules downstream of the NKR, such as TYROBP, 
FCER1G, but also SYK and PLCG2, were highly expressed in dif-
ferent entities such as PTCL-NOS (Supplemental Figure 5D). The 
heterogeneity of PTCL-NOS for the expression of this NK gene 
signature led us to analyze it within the 2 recently reported molec-
ular subclassifications TBX21 and GATA3 (36). The NK gene sig-
nature was significantly enriched in PTCL-TBX21 compared with 
PTCL-GATA3 (P = 0.04, FDR = 0.09; Supplemental Figure 5, E 
and F), in agreement with the high T-bet expression in mPTCLs. 
Finally, in the TBX21 subgroup, high expression of the NK gene 
signature was associated with poor overall survival (P = 0.04; 
Supplemental Figure 5G).
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TCR engagement to these PTCLs: (a) the transfer of p53–/– T lym-
phocytes in the absence of chronic TCR stimulation (p53KO>WT 
mice) did not trigger PTCL development; (b) mPTCL cells 
showed typical features of memory effector T cells, with some 
PTCL cells expressing exhaustion makers such as programmed 
cell death 1 (PD-1) and Lag3; (c) GSEA indicated a significant 
downregulation of genes in the TCR signaling pathway, as pre-
viously reported for chronically TCR-stimulated T cells (29); 
and (d) downregulation of CD28 and expression of NKRs on T 
cells have been associated with chronic TCR antigenic stimula-
tion (40). In addition to chronic TCR stimulation, p53 deficiency 
was a driver event in T cell lymphomagenesis in this model, as 
suggested by the absence of PTCL development in WT>CD3ε–/– 
mice. This result is consistent with recent studies demonstrating 
the high prevalence of TP53 gene expression or downstream 
pathway alterations in several entities of human PTCL, in par-
ticular non–TFH-PTCL-NOS (4, 25), suggesting a driver role of 
TP53 in T cell lymphomagenesis. However, p53 deficiency alone 
was not sufficient, as seen by the lack of PTCL development in 
the absence of chronic TCR stimulation in p53KO>WT mice. 
These data are in line with previous reports demonstrating that 
p53–/– mice mainly develop immature thymic lymphomas (41, 
42) and CD1d-restricted NK T cell lymphomas, but more rarely 
PTCLs originating from conventional T cells (23, 24).
Most PTCLs generated in our study model exhibited a NK-like 
phenotype consistent with a reprogramming that was probably the 
consequence of chronic TCR stimulation. Indeed, NKR+ T cells, 
in particular NKR+ CD8+ T cells, have been associated with anti-
gen-experienced T cells during chronic infection (40, 43) and in 
autoimmune disorders such as systemic lupus erythematosus 
(SLE) (44), rheumatoid arthritis (45), and celiac disease (46). In 
addition to chronic TCR stimulation, IL-15 was recently described 
as a key driver in this reprogramming during acute hepatitis A 
infection, in which memory CD8+ T cells expressed NKG2D and 
NKp30 (47), and in patients with SLE with NKp30-expressing 
CD8+ T cells (44). In the mPTCL model presented here, the main-
tenance of CD122 expression, even though CD25 was downregu-
lated, was consistent with a joint role of chronic TCR stimulation 
and IL-15 in the NK-like reprogramming. In normal thymocytes 
and mature CD8+ T cells, reprogramming toward NK-like cells has 
been described upon Bcl11b deletion (33). These reprogrammed 
NK-like cells are fully functional, since they can kill tumor cells 
in vitro and prevent tumor metastasis in vivo (33). In our model, 
further study will be necessary to ascertain whether Bcl11b down-
regulation is first triggered by chronic TCR stimulation that conse-
quently leads to NK-like reprogramming.
NKRs, in particular NKaRs, appeared to be markers of gen-
eral NK-like reprogramming. The results of our study empha-
sized their functional role in PTCL in major cellular pathways, 
such as those for cytotoxicity, proliferation, and/or survival. 
So, NKaR genetic invalidation or blocking antibodies targeting 
NKp46 and NKG2D significantly delayed PTCL development in 
vivo, highlighting the importance of these NKaRs in PTCL sur-
vival (Figure 8, A and B). Involvement of NKaRs in normal NK 
and T cell survival and proliferation was formerly established 
in particular with NKG2C, Ly49D, and DNAM1 (46, 48–53). 
In addition, engagement of CD16 strongly supports leukemia 
genes was significantly delayed, demonstrating the contribution 
of NKaRs to mPTCL survival in vivo (Figure 8A). From a thera-
peutic perspective, we also sought to determine whether pharma-
cological inhibition of these receptors with blocking mAbs could 
delay PTCL development in vivo. Such treatments were indeed 
sufficient to delay mPTCL development and significantly improve 
mouse survival compared with isotype antibody–treated con-
trol animals (Figure 8B). This effect was even stronger when we 
injected both anti-NKG2D– and anti-NKp46–blocking antibodies 
(Figure 8B), as shown by the decrease in spleen and liver volumes 
(Figure 8, C and D), as well as spleen and liver weights and lym-
phoma cell counts (Supplemental Figure 6, B and C). In addition, 
and consistent with the role of SYK, PLCγ2, AKT, and S6 kinases 
downstream of the NKaR, treatment of mice with anti-NKG2D– 
and anti-NKp46–blocking antibodies reduced the constitutive 
activation of these kinases in mPTCL cells (Figure 8E).
We then designed a series of experiments to inhibit NKaR 
signaling in mPTCL in vivo. We first genetically invalidated 
Syk in mPTCL by CRISPR/Cas9, which resulted in a decrease 
in SYK expression (Supplemental Figure 6D) and prolonged 
survival of mice injected with such tumor cells as compared 
with the control mice (Figure 8F). We then confirmed these 
data using chemical inhibitors of SYK (P505-15 or cerdulatinib) 
or of the downstream complex mTORC1 (rapamycin) (Figure 
8, G and H). To further study the role of the NKaR in mPTCL 
survival in vivo, we investigated the expression of the NKG2D 
ligands Rae and H60 in the tumor microenvironment of the 
spleen. We did not include the NKp46 endogenous ligand in 
this analysis, since this ligand remains unknown. Whereas 
H60 was negative in all samples tested, we found that Rae was 
expressed on some PTCL cells and CD31+ endothelial cells, as 
previously described (39), but was undetectable on normal T 
and B lymphocytes or on CD11c+ and CD11b+ cells (Supplemen-
tal Figure 6, E and F). Altogether, these results demonstrate 
that mPTCL cell survival is at least partially dependent on 
NKaR/SYK/mTOR activation through potential interaction 
of these receptors with their ligands expressed in the tumor 
microenvironment or directly on PTCL cells.
Discussion
In the present study, we developed a model in which chronic 
TCR stimulation was based on homeostatic proliferation that 
enabled polyclonal T cell activation and proliferation. Most of 
the mice receiving p53–/– T cells ultimately developed PTCL, and 
several lines of evidence suggested a contribution of chronic 
Figure 6. Murine and human PTCLs express NKRs. (A) Representative 
histograms of NK1.1, NKp46, NKG2D, KLRG1, Ly49C, and NKG2A expression 
measured by flow cytometry in a single mPTCL. Associated scatter plots 
show expression in T cells (n = 5), NK cells (n = 5), and mPTCL cells (n = 23) 
for each NKR. P values were determined by Mann-Whitney U test compar-
ing mPTCL cells and normal T cells. (B) Representative histograms of NKR 
expression in 2 human PTCLs measured by flow cytometry. (C) Scatter plot 
of expression of 8 different NKRs in 8 human PTCL entities established 
from the flow cytometric studies depicted in B. TFH-PTCL encompasses 
AITL and PTCL-NOS with TFH-like features according to the 2016 WHO 
classification. LNH NK, non-Hodgkin lymphoma from NK cells; T-PLL, T cell 
prolymphocytic leukemia.
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activates various signaling pathways, such as PI3K/AKT/mTOR, 
RAS/ERK, and PLCγ (63–65), mimicking chronic TCR signaling 
that could lead to NKR and SYK expression. Expression of the NKR 
and SYK in ALK– ALCL could also be due to chronic TCR stimu-
lation. This was recently suggested in breast implant–associated 
ALK– ALCL, in which downregulation of TCR signaling genes was 
evidenced by GSEA (21). Interestingly, a profound downmodula-
tion of BCL11b expression has been associated with BCL11B pro-
moter methylation in ALCL (66), suggesting that NK-like repro-
gramming of ALCL could also be driven by the loss of BCL11b 
expression. Whether this is also the consequence of chronic TCR 
stimulation requires further experiments. Thus, the expression of 
SYK and NKRs by ALCL cells could result from lymphomagene-
sis steps similar to those observed in our mouse model, especially 
since this entity shows recurrent p53 pathway alterations (67).
In conclusion, our results provide evidence that chronic TCR 
stimulation triggers PTCL development. This chronic TCR stimu-
lation promotes epigenetic T cell reprogramming toward NK-like 
cells, downregulating several T cell–specific genes, such as Bcl11b 
and inducing several NK cell features, such as NKRs and their 
signaling molecules. We also demonstrated that this NK-like 
reprogramming induced addiction to SYK and NKaR signaling to 
maintain PTCL survival, whereas TCR signaling was mostly inef-
fective. Thus, we found that TCR signaling, despite being required 
for lymphomagenesis, does not constitute an optimal target in 
established PTCL, as previously reported in AITL (13). Our inves-
tigations led us to propose that NKR and SYK expression in several 
human PTCL entities emerging from conventional T cells could 
result from chronic TCR stimulation and epigenetic NK-like repro-
gramming. We believe our study has important clinical implica-
tions and highlights the potential interest of immunotherapies tar-
geting the NKR in human PTCLs. One direct outcome of this work 
may be to foster the use of the anti-KIR3DL2 humanized cytotoxic 
antibody lacutamab (IPH4102), not only to treat CTCLs but also 
to treat KIR3DL2+ PTCLs, which represent more than 30% of 
the cohort tested in our human study. In addition to the TELLO-
MAK clinical trial (NTC03902184), a new multi-cohort phase II 
trial focused on anti-KIR in T cell lymphoma (KILT) is currently 
underway to assess the impact of lacutamab in combination with 
gemcitabine and oxaliplatin (GEMOX) in such PTCLs at relapse. 
In addition to previous reports (62, 68), our study also reveals 
the clinical translational finding that some PTCLs show consti-
tutive expression and activation of SYK, raising the possibility of 
testing new SYK inhibitors in patients with PTCL, as illustrated 
by the encouraging results from a phase II trial of cerdulatinib 
(NCT04021082) that demonstrated responses in 35% of patients 
with PTCL and in 35% of those with CTCL (69).
Methods
See Supplemental Methods for further details.
Data availability. Microarray data from mPTCLs and normal con-
trol T cells have been deposited in the NCBI’s Gene Expression Omni-
bus (GEO) database (GEO GSE174257) Microarray data from Immu-
nological Genome Project (ImmGen) murine populations (www.
ImmGen.org) were collected from the ImmGen database (accession 
number GPL6246). ATAC-Seq data from mPTCLs and normal control 
T cells, as well as from NKT cells and NK cells have been deposited in 
cell proliferation in T-LGL (54, 55), and KIR3DL2 regulates cell 
survival of Sézary cells by inhibiting apoptosis induced by TCR 
stimulation (56).
In humans, we identified several PTCL entities, such as 
T-LGL and SS, that expressed most of the NKRs tested in our 
study. The role of chronic TCR stimulation in these entities has 
been proposed (19, 20), however, whether NKR expression is trig-
gered by chronic TCR stimulation or other chronic inflammato-
ry signals such as IL-15, which has undoubtedly been associated 
with lymphomagenesis of these 2 entities (31, 32), is still a matter 
of debate. NKaR expression has been described in several other 
human PTCL entities and is often considered a hallmark of the 
innate-like T cell origin of these PTCLs (57–59). Indeed, a NK-like 
cytotoxic signature has been described in MEITL that may be 
associated with the γδ T cell origin of these lymphoma cells (59). 
However, whole-exome sequencing revealed that 30% of MEITLs 
had BCL11B mutations (59), suggesting that reprogramming may 
also explain this NK-like signature. Results from our mouse mod-
el may also lead to a reconsideration of the cell of origin of these 
PTCLs as the only explanation for this NK cell–like phenotype, 
since we demonstrated that chronically stimulated conventional T 
cells reprogram into innate-like T cells expressing NKaRs.
Our analysis of transcriptomic data revealed that approxi-
mately 50% of PTCL-NOSs exhibited a NK gene signature that 
was mostly associated with the PTCL-TBX21 subgroup and a poor 
clinical outcome for patients, in line with previous reports (36). We 
also unraveled the expression of several NKRs on ALK– and ALK+ 
ALCL cells, as already partially described in previous studies (60). 
SYK and PLCγ2 are also expressed in a significant proportion of 
ALCLs, especially in ALK+ cases, corroborating previous data 
reporting SYK expression in CD30+ PTCL (61) and SYK-depen-
dent growth and survival of ALK+ PTCL cell lines (62). In the case 
of ALK+ ALCL, nucleophosmin-ALK (NPM-ALK) fusion protein 
Figure 7. NKRs are functional and signal through SYK in mPTCLs. (A) 
Western blots showing expression of the adaptor proteins FcεRIg and 
DAP12 in 9 mPTCL samples. Enriched NK cells and sorted B and T cells 
were used as positive and negative controls, respectively. GAPDH was 
used as a loading control. (B) Representative FACS analysis of CD107a 
and IFN-γ expression in a cytotoxicity assay of mPTCL cells in the basal 
state and after NKaR or TCR-CD3 complex activation. Scatter plot shows 
CD107a (black) and IFN-γ (red) expression in the basal state (n = 12), after 
anti-CD3/anti-CD28 (n = 9, PTCL cells expressing low levels of CD3 were 
not analyzed) and after NKR activation (n = 12) (right panel). *P < 0.05, **P 
< 0.01, ***P < 0.001, and ****P < 0.0001, by Mann-Whitney U test with 
Holm’s post hoc correction. (C) Representative FACS analysis of CD107a 
and IFN-γ expression in mPTCL cells in the basal state or activated with 
anti-CD3/CD28 (α-CD3) or anti-NKaR (α-NKaRs) in the presence of vehicle 
or P505-15. Data are representative of 2 different mPTCLs. (D) Representa-
tive FACS analysis of granzyme B expression in mPTCL cells (red) compared 
with staining with an isotype control (black). Scatter plot shows granzyme 
B expression in normal T cells (n = 3), NK cells (n = 3), and mPTCL cells (n = 
9). *P < 0.05, by Mann-Whitney U test comparing mPTCL cells and normal 
T cells. (E) Western blots show pY1217-PLCγ2 and total PLCγ2 expression in a 
representative mPTCL in the basal state and after NKaR in vitro activa-
tion in the presence of vehicle or P505-15. The relative phosphorylation 
of pY1217-PLCγ2/total PLCγ2 of 4 mPTCLs was quantified in these different 
conditions. Sorted stimulated B and T cells from WT mice were used as 
positive and negative controls, respectively. GAPDH was used as a loading 
control. *P < 0.05, by Mann-Whitney U test.
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(CHLS) and the TENOMIC consortium. For all human samples, the 
patients provided written informed consent.
The clinical outcomes of the patients with PTCL-NOS described 
in Supplemental Figure 5 were previously reported (36).
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low a normal distribution. A P value of less than 0.05 was considered 
statistically significant. Survival in mouse experiments is represented 
as a Kaplan-Meier curve, and the log-rank test was used to determine 
the significance. All of the experiments were repeated at least twice, 
and representative images are shown.
Study approval. All animal studies and procedures were performed 
in accordance with European Union guidelines and approved by the 
local Animal Ethics Evaluation Committee (CECCAPP, SFR Bioscienc-
es, Gerland, France, UMS3444/US8). Human samples used for flow 
cytometric analysis were obtained from frozen cell suspension collec-
tions from the Centre de Resources Biologiques of the Centre Hospi-
talier Lyon Sud and the Centre Hospitalier Universitaire Grenoble Alpes 
and from the CeVi collection of the Institute Carnot/CALYM (ANR, 
France; https://www.calym.org/-Viable-cell-collection-CeVi-.html).
For histopathology and IHC, paraffin-embedded samples were 
obtained from tissue collections of the Centre Hospitalier Lyon Sud 
Figure 8. mPTCL cells rely on NKaR signaling for survival. (A) Kaplan-Mei-
er survival curves for WT mice (n = 5 for each group) transferred with 
mPTCL cells genetically invalidated for Klrk1 (sgNKG2D), Ncr1 (sgNKp46), or 
both, using Alt-R CRISPR/Cas9 sgRNA targeting these genes, or transfect-
ed with control sgRNA. **P  < 0.01, by log-rank test with Holm’s post hoc 
correction. Data are representative of 2 independent experiments using 
different mPTCL cells. (B) Kaplan-Meier survival curves for mPTCL-bearing 
NSG mice treated with isotype control or anti-NKp46– and anti-NKG2D–
blocking mAbs alone or in combination (n = 6 for each group). **P  < 0.01, 
by log-rank test with Holm’s post hoc correction. Data are representative 
of 3 independent experiments using different PTCLs. (C) Representative 3D 
reconstruction of spleen and liver of mPTCL-bearing NSG mice treated with 
isotype control or a combination of anti-NKp46– and anti-NKG2D–blocking 
mAbs and sacrificed 12 days after PTCL transfer for analysis. (D) Spleen 
and liver volumes of mPTCL-bearing NSG mice treated with a combination 
of anti-NKp46– and anti-NKG2D–blocking mAbs or isotype control 12 days 
after PTCL transfer (isotype control group, n = 5; mAb-treated group, n = 
5). P values were determined by Mann-Whitney U test. (E) FACS analysis 
of p-SYK, p-PLCγ2, p-AKT, and p-S6 and associated scatter plots of mPTCL 
cells from PTCL-bearing mice treated with anti-NKG2D– and anti-NKp46–
blocking mAbs (n = 4) or isotype control (n = 4). (F) Kaplan-Meier survival 
curves for WT mice (n = 5 for each group) transferred with mPTCL cells 
genetically invalidated for Syk (sgSYK) or transfected with control sgRNA. 
P value was determined by log-rank test. Data are representative of 2 inde-
pendent experiments using different mPTCLs. (G) Kaplan-Meier survival 
curves for mPTCL-bearing NSG mice treated with vehicle alone (Ctrl) or with 
either P505-15 (20 mg/kg) or cerdulatinib (20 mg/kg). *P < 0.05 and **P < 
0.01, by log-rank test with Holm’s post hoc correction. Data are representa-
tive of 2 independent experiments using different PTCLs. (H) Kaplan-Meier 
survival curves for mPTCL-bearing NSG mice treated with vehicle control or 
rapamycin. P value was determined by log-rank test. Data are representa-
tive of 2 independent experiments using different PTCLs.
 1. Swerdlow SH, et al. The 2016 revision of 
the World Health Organization classi-
fication of lymphoid neoplasms. Blood. 
2016;127(20):2375–2390.
 2. Fiore D, et al. Peripheral T cell lymphomas: 
from the bench to the clinic. Nat Rev Cancer. 
2020;20(6):323–342.
 3. Pechloff K, et al. The fusion kinase ITK-SYK 
mimics a T cell receptor signal and drives 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(13):e139675  https://doi.org/10.1172/JCI1396751 6
oncogenesis in conditional mouse models 
of peripheral T cell lymphoma. J Exp Med. 
2010;207(5):1031–1044.
 4. Choi J, et al. Genomic landscape of cutaneous T 
cell lymphoma. Nat Genet. 2015;47(9):1011–1019.
 5. Ungewickell A, et al. Genomic analysis of  
mycosis fungoides and Sézary syndrome identi-
fies recurrent alterations in TNFR2. Nat Genet. 
2015;47(9):1056–1060.
 6. da Silva Almeida AC, et al. The mutational land-
scape of cutaneous T cell lymphoma and Sezary 
syndrome. Nat Genet. 2015;47(12):1465–1470.
 7. Kataoka K, et al. Integrated molecular analysis 
of adult T cell leukemia/lymphoma. Nat Genet. 
2015;47(11):1304–1315.
 8. Palomero T, et al. Recurrent mutations in 
epigenetic regulators, RHOA and FYN kinase 
in peripheral T cell lymphomas. Nat Genet. 
2014;46(2):166–170.
 9. Yoo HY, et al. A recurrent inactivating mutation 
in RHOA GTPase in angioimmunoblastic T cell 
lymphoma. Nat Genet. 2014;46(4):371–375.
 10. Sakata-Yanagimoto M, et al. Somatic RHOA 
mutation in angioimmunoblastic T cell  
lymphoma. Nat Genet. 2014;46(2):171–175.
 11. Vallois D, et al. Activating mutations in genes 
related to TCR signaling in angioimmunoblastic 
and other follicular helper T cell-derived lym-
phomas. Blood. 2016;128(11):1490–1502.
 12. Abate F, et al. Activating mutations and translo-
cations in the guanine exchange factor VAV1 in 
peripheral T cell lymphomas. Proc Natl Acad Sci 
U S A. 2017;114(4):764–769.
 13. Cortes JR, et al. RHOA G17V Induces T follicular 
helper cell specification and promotes lymphom-
agenesis. Cancer Cell. 2018;33(2):259–273.
 14. Ng SY, et al. RhoA G17V is sufficient to induce 
autoimmunity and promotes T cell lymphoma-
genesis in mice. Blood. 2018;132(9):935–947.
 15. Warner K, et al. T cell receptor signaling in 
peripheral T cell lymphoma - a review of patterns 
of alterations in a central growth regulatory path-
way. Curr Hematol Malig Rep. 2013;8(3):163–172.
 16. Murray A, et al. Study of the immunohisto-
chemistry and T cell clonality of enteropa-
thy-associated T cell lymphoma. Am J Pathol. 
1995;146(2):509–519.
 17. Ritter J, et al. T cell repertoires in refractory  
coeliac disease. Gut. 2018;67(4):644–653.
 18. Belhadj K, et al. Hepatosplenic gammadelta T 
cell lymphoma is a rare clinicopathologic enti-
ty with poor outcome: report on a series of 21 
patients. Blood. 2003;102(13):4261–4269.
 19. Garrido P, et al. Monoclonal TCR-Vbeta13.1+/
CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: 
evidence for an antigen-driven chronic T cell stim-
ulation origin. Blood. 2007;109(11):4890–4898.
 20. Tothova SM, et al. Mycosis fungoides: is it a  
Borrelia burgdorferi-associated disease?  
Br J Cancer. 2006;94(6):879–883.
 21. Di Napoli A, et al. Transcriptional analysis dis-
tinguishes breast implant-associated anaplastic 
large cell lymphoma from other peripheral T cell 
lymphomas. Mod Pathol. 2019;32(2):216–230.
 22. Wang X, et al. TCR-dependent transformation  
of mature memory phenotype T cells in mice.  
J Clin Invest. 2011;121(10):3834–3845.
 23. Bachy E, et al. CD1d-restricted peripheral T 
cell lymphoma in mice and humans. J Exp Med. 
2016;213(5):841–857.
 24. Robinot R, et al. Chronic Borrelia burgdorferi 
infection triggers NKT lymphomagenesis. Blood. 
2018;132(25):2691–2695.
 25. Watatani Y, et al. Molecular heterogeneity in 
peripheral T cell lymphoma, not otherwise speci-
fied revealed by comprehensive genetic profiling. 
Leukemia. 2019;33(12):2867–2883.
 26. Crescenzo R, et al. Convergent mutations and 
kinase fusions lead to oncogenic STAT3 activa-
tion in anaplastic large cell lymphoma. Cancer 
Cell. 2015;27(4):516–532.
 27. Jiang L, et al. Exome sequencing identi-
fies somatic mutations of DDX3X in nat-
ural killer/T cell lymphoma. Nat Genet. 
2015;47(9):1061–1066.
 28. Surh CD, Sprent J. Homeostasis of naive and 
memory T cells. Immunity. 2008;29(6):848–862.
 29. Baniyash M. TCR zeta-chain downregulation: 
curtailing an excessive inflammatory immune 
response. Nat Rev Immunol. 2004;4(9):675–687.
 30. Sato N, et al. Development of an IL-15-autocrine 
CD8 T cell leukemia in IL-15-transgenic mice 
requires the cis expression of IL-15R. Blood. 
2011;117(15):4032–4040.
 31. Mishra A, et al. Aberrant overexpression of 
IL-15 initiates large granular lymphocyte 
leukemia through chromosomal instability 
and DNA hypermethylation. Cancer Cell. 
2012;22(5):645–655.
 32. Mishra A, et al. Mechanism, consequences, and 
therapeutic targeting of abnormal IL15 signaling 
in cutaneous T cell lymphoma. Cancer Discov. 
2016;6(9):986–1005.
 33. Li P, et al. Reprogramming of T cells to natural 
killer-like cells upon Bcl11b deletion. Science. 
2010;329(5987):85–89.
 34. Daussy C, et al. T-bet and Eomes instruct the 
development of two distinct natural killer cell  
lineages in the liver and in the bone marrow.  
J Exp Med. 2014;211(3):563–577.
 35. Travert M, et al. Molecular features of 
hepatosplenic T cell lymphoma unravels 
potential novel therapeutic targets. Blood. 
2012;119(24):5795–5806.
 36. Iqbal J, et al. Gene expression signatures 
delineate biological and prognostic sub-
groups in peripheral T cell lymphoma. Blood. 
2014;123(19):2915–2923.
 37. Lima M. Extranodal NK/T cell lymphoma and 
aggressive NK cell leukaemia: evidence for their 
origin on CD56+bright CD16-/+dim NK cells. 
Pathology. 2015;47(6):503–514.
 38. Bagot M, et al. IPH4102, a first-in-class anti-
KIR3DL2 monoclonal antibody, in patients with 
relapsed or refractory cutaneous T cell lympho-
ma: an international, first-in-human, open-label, 
phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170.
 39. Thompson TW, et al. Endothelial cells express 
NKG2D ligands and desensitize antitumor NK 
responses. Elife. 2017;6:e30881.
 40. Seyda M, et al. T cells going innate. Trends Immu-
nol. 2016;37(8):546–556.
 41. Donehower LA, et al. Mice deficient for 
p53 are developmentally normal but sus-
ceptible to spontaneous tumours. Nature. 
1992;356(6366):215–221.
 42. Jacks T, et al. Tumor spectrum analysis in 
p53-mutant mice. Curr Biol. 1994;4(1):1–7.
 43. Seich Al Basatena NK, et al. KIR2DL2 enhances 
protective and detrimental HLA class I-mediated 
immunity in chronic viral infection. PLoS Pathog. 
2011;7(10):e1002270.
 44. Correia MP, et al. Distinct human circulating 
NKp30+FcεRIγ+CD8+ T cell population exhibiting 
high natural killer-like antitumor potential. Proc 
Natl Acad Sci U S A. 2018;115(26):E5980–E5989.
 45. Yen JH, et al. Major histocompatibility com-
plex class I-recognizing receptors are disease 
risk genes in rheumatoid arthritis. J Exp Med. 
2001;193(10):1159–1167.
 46. Meresse B, et al. Reprogramming of CTLs into 
natural killer-like cells in celiac disease. J Exp 
Med. 2006;203(5):1343–1355.
 47. Kim J, et al. Innate-like cytotoxic function of 
bystander-activated CD8+ T cells is associated 
with liver injury in acute hepatitis A. Immunity. 
2018;48(1):161–173.
 48. Smith HR, et al. Recognition of a virus-encoded 
ligand by a natural killer cell activation receptor. 
Proc Natl Acad Sci U S A. 2002;99(13):8826–8831.
 49. Brown MG, et al. Vital involvement of a natural 
killer cell activation receptor in resistance to viral 
infection. Science. 2001;292(5518):934–937.
 50. Daniels KA, et al. Murine cytomegalovirus is reg-
ulated by a discrete subset of natural killer cells 
reactive with monoclonal antibody to Ly49H.  
J Exp Med. 2001;194(1):29–44.
 51. Dokun AO, et al. Specific and nonspecific NK cell 
activation during virus infection. Nat Immunol. 
2001;2(10):951–956.
 52. Lopez-Verges S, et al. Expansion of a 
unique CD57(+)NKG2Chi natural killer 
cell subset during acute human cytomega-
lovirus infection. Proc Natl Acad Sci U S A. 
2011;108(36):14725–14732.
 53. Nabekura T, et al. Costimulatory molecule 
DNAM-1 is essential for optimal differenti-
ation of memory natural killer cells during 
mouse cytomegalovirus infection. Immunity. 
2014;40(2):225–234.
 54. Hoshino S, et al. Activation via the CD3 and 
CD16 pathway mediates interleukin-2-depen-
dent autocrine proliferation of granular lympho-
cytes in patients with granular lymphocyte prolif-
erative disorders. Blood. 1991;78(12):3232–3240.
 55. Cambiaggi A, et al. The natural killer-related 
receptor for HLA-C expressed on T cells from 
CD3+ lymphoproliferative disease of granular 
lymphocytes displays either inhibitory or stimu-
latory function. Blood. 1996;87(6):2369–2375.
 56. Ghazi B, et al. KIR3DL2/CpG ODN interaction 
mediates Sézary syndrome malignant T cell 
apoptosis. J Invest Dermatol. 2015;135(1):229–237.
 57. Uemura Y, et al. Expression of activating natural 
killer-cell receptors is a hallmark of the innate-
like T cell neoplasm in peripheral T cell lympho-
mas. Cancer Sci. 2018;109(4):1254–1262.
 58. Ettersperger J, et al. Interleukin-15-dependent 
T cell-like innate intraepithelial lymphocytes 
develop in the intestine and transform into 
lymphomas in celiac disease. Immunity. 
2016;45(3):610–625.
 59. Moffitt AB, et al. Enteropathy-associated T 
cell lymphoma subtypes are characterized 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 7J Clin Invest. 2021;131(13):e139675  https://doi.org/10.1172/JCI139675
by loss of function of SETD2. J Exp Med. 
2017;214(5):1371–1386.
 60. Freud AG, et al. Expression of the activating 
receptor, NKp46 (CD335), in human natural 
killer and T cell neoplasia. Am J Clin Pathol. 
2013;140(6):853–866.
 61. Bisig B, et al. CD30-positive peripheral T cell 
lymphomas share molecular and phenotypic fea-
tures. Haematologica. 2013;98(8):1250–1258.
 62. Wilcox RA, et al. Inhibition of Syk protein tyro-
sine kinase induces apoptosis and blocks prolif-
eration in T cell non-Hodgkin’s lymphoma cell 
lines. Leukemia. 2010;24(1):229–232.
 63. Slupianek A, et al. Role of phosphatidylinositol 
3-kinase-Akt pathway in nucleophosmin/ana-
plastic lymphoma kinase-mediated lymphoma-
genesis. Cancer Res. 2001;61(5):2194–2199.
 64. Bai RY, et al. Nucleophosmin-anaplastic lympho-
ma kinase of large-cell anaplastic lymphoma is a 
constitutively active tyrosine kinase that utilizes 
phospholipase C-gamma to mediate its mitoge-
nicity. Mol Cell Biol. 1998;18(12):6951–6961.
 65. Amin HM, Lai R. Pathobiology of ALK+ 
anaplastic large-cell lymphoma. Blood. 
2007;110(7):2259–2267.
 66. Hassler MR, et al. Insights into the pathogene-
sis of anaplastic large-cell lymphoma through 
genome-wide DNA methylation profiling. Cell 
Rep. 2016;17(2):596–608.
 67. Parrilla Castellar ER, et al. ALK-negative anaplas-
tic large cell lymphoma is a genetically hetero-
geneous disease with widely disparate clinical 
outcomes. Blood. 2014;124(9):1473-80.
 68. Feldman AL, et al. Overexpression of Syk tyrosine 
kinase in peripheral T cell lymphomas. Leukemia. 
2008;22(6):1139–1143.
 69.  Horwitz SM, et al. A phase 2 study of the dual 
SYK/JAK inhibitor cerdulatinib demonstrates 
good tolerability and clinical response in 
relapsed/refractory peripheral T-cell lympho-
ma and cutaneous T-cell lymphoma. Blood. 
2019;134(Suppl 1):466.
